selected publications
- Corrigendum to Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression, Cancer Treatment and Research Communications 46 (2026) 101109. Cancer treatment and research communications. 2026 Article GET IT
- Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression. Cancer treatment and research communications. 2026 Academic Article GET IT
- Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2026 Academic Article GET IT
-
The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non-small cell lung cancer.
Journal of the National Cancer Institute.
2026
Academic Article
GET IT
Times cited: 3 -
Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison.
Journal of comparative effectiveness research.
2025
Academic Article
GET IT
Times cited: 1 - The impact of preoperative imaging strategies in EGFR-mutant non-small cell lung cancer: a multicenter retrospective review. medRxiv : the preprint server for health sciences. 2025 Article GET IT
- Second-line therapy following osimertinib in metastatic EGFR-mutated non-small cell lung cancer at an academic medical center. medRxiv : the preprint server for health sciences. 2025 Article GET IT
-
Neoadjuvant nonablative stereotactic body radiotherapy plus immunotherapy yields similar pathologic response as chemoimmunotherapy in non-small cell lung cancer.
The Journal of thoracic and cardiovascular surgery.
2025
Academic Article
GET IT
Times cited: 2 - Expanding the Clinical Phenotype of Autosomal Recessive Chronic Granulomatous Disease. Journal of clinical immunology. 2024 Article GET IT
-
Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons.
Clinical lung cancer.
2024
Academic Article
GET IT
Times cited: 9 -
Integrating Health Equity in the ASCO Guideline Agenda: Recommendations From Members of the Palliative Care Expert Panel.
JCO oncology practice.
2024
Academic Article
GET IT
Times cited: 4 -
Top Ten Tips Palliative Care Clinicians Should Know About Caring for Filipino American and Korean American Patients.
Journal of palliative medicine.
2023
Academic Article
GET IT
Times cited: 6 -
Diagnosis of immune thrombocytopenia, including secondary forms, and selection of second-line treatment.
Haematologica.
2022
Academic Article
GET IT
Times cited: 14 -
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020
Article
GET IT
Times cited: 110 -
Standardization of Inpatient CPR Status Discussions and Documentation Within the Division of Hematology-Oncology at UPMC Shadyside: Results From PDSA Cycles 1 and 2.
Journal of oncology practice.
2019
Academic Article
GET IT
Times cited: 5 -
Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.
Journal for immunotherapy of cancer.
2018
Article
GET IT
Times cited: 44 -
Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2018
Article
GET IT
Times cited: 2 -
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Haematologica.
2018
Academic Article
GET IT
Times cited: 154 -
Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis.
Cancer investigation.
2017
Information Resource
GET IT
Times cited: 5 -
Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.
Cancer investigation.
2016
Information Resource
GET IT
Times cited: 27 - Learning From Errors: Curriculum Guide for the Morbidity and Mortality Conference With a Focus on Patient Safety Concepts. MedEdPORTAL : the journal of teaching and learning resources. 2016 Academic Article GET IT
-
Atrial Myxoma: A Case Presentation and Review.
Cardiology research.
2012
Article
GET IT
Times cited: 13 - Cavernous transformation of portal vein secondary to portal vein thrombosis: a case report. Journal of clinical medicine research. 2012 Article GET IT
- Heparin induced thrombocytopenia: case presentation and review. Journal of clinical medicine research. 2012 Academic Article GET IT